High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels:: Molecular predictors for survival of stage 2 soft tissue sarcoma patients

被引:0
|
作者
Köhler, T
Würl, P
Meye, A
Lautenschläger, C
Bartel, F
Borchert, S
Bache, M
Schmidt, H
Holzhausen, HJ
Taubert, H
机构
[1] Univ Halle Wittenberg, Inst Pathol, D-06097 Halle An Der Saale, Germany
[2] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany
[3] Univ Leipzig, Clin Surg 1, Leipzig, Germany
[4] Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle An Der Saale, Germany
[5] Univ Halle Wittenberg, Dept Radiotherapy, D-06097 Halle An Der Saale, Germany
[6] Univ Dresden, Urol Clin, Dresden, Germany
关键词
soft tissue sarcoma; prognostic markers; bad; bax; bcl-xL bcl-2; mRNA expression; quantitative; high-throughput RT-PCR; 5 ' nuclease assay; DNA-coated strips;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of the bcl-2 gene family members in promoting or antagonizing apoptosis in malignant tumors, including soft tissue sarcomas (STS), is well known. However, the impact of mRNA expression of bcl-2 family genes on prognosis has not been thoroughly investigated in STS. Samples from 82 STS patients were analyzed for mRNA expression of bad, bax, bcl-x(L) and bcl-2 by a high-throughput quantitative RTPCR approach, using validated assays based on TaqMan(R) technology. The mRNA data, related to glyceraldehyde-3-phosphate dehydrogenase expression measured in the same sample, were analysed for their correlation to tumor stage and overall survival of patients. In a Kaplan-Meier analysis none of the mRNA levels investigated differed significantly with regard to their impact on survival (log-rank test). However, after including the tumor stage in the statistical analysis, a borderline significance was observed for bad mRNA expression (p=0.068) indicating a stage-specific impact of mRNA expression on prognosis. Considering STS patients of tumor stage 2, multivariate Cox analysis revealed that bad mRNA values greater than or equal to10 (p=0.0039; RR=9.08), bcl-x(L) greater than or equal to1.5 (p=0.067; RR = 4.59), bax greater than or equal to0.005 (p=0.1; RR=2.84) and bcl-2 <3 (p=0.42; RR=1.7) were associated with a poor prognosis. Combined high bad/bcl-x(L) mRNA expression levels revealed a 20 fold increase in the relative risk of tumor-related death (p=0.016) when comparing the poor and good prognosis groups. There was a 14.5 fold and 6.5-fold increase in the risk for the combinations of high bax/bcl-x(L) mRNA (p=0.018) and bax/bcl-2 mRNA expression (p=0.017), respectively. In conclusion, high bad mRNA levels and combined values of bad/bcl-x(L), bax/bcl-x(L) and bax/bcl-2 appear to be independent prognostic factors at least for stage 2 STS patients. In the combinations of mRNA levels there was more than an additive effect pointing to different pathways of prognostic relevance.
引用
收藏
页码:1553 / 1559
页数:7
相关论文
共 50 条
  • [31] Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck
    Pena, JC
    Thompson, CB
    Recant, W
    Vokes, EE
    Rudin, CM
    CANCER, 1999, 85 (01) : 164 - 170
  • [32] Expression of bcl-2 and bcl-xL in cutaneous and bone marrow lesions of mastocytosis
    Hartmann, K
    Artuc, M
    Baldus, SE
    Zirbes, TK
    Hermes, B
    Thiele, J
    Mekori, YA
    Henz, BM
    AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (03): : 819 - 826
  • [33] Expression of Bax, Bcl-xL and Bcl-2 proteins in relation to grade of inflammation and stage of fibrosis in chronic hepatitis C
    Piekarska, A.
    Kubiak, R.
    Szymczak, W.
    Piekarski, J.
    HISTOPATHOLOGY, 2007, 50 (07) : 928 - 935
  • [34] Distinct domains of Bcl-XL are involved in Bax and Bad antagonism and in apoptosis inhibition
    Zhou, H
    Hou, Q
    Chai, YF
    Hsu, YT
    EXPERIMENTAL CELL RESEARCH, 2005, 309 (02) : 316 - 328
  • [36] Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas
    Ogura, E
    Senzaki, H
    Yamamoto, D
    Yoshida, R
    Takada, H
    Hioki, K
    Tsubura, A
    ONCOLOGY REPORTS, 1999, 6 (02) : 365 - 369
  • [37] Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists
    Schroeder, Gretchen M.
    Wei, Donna
    Banfi, Patrizia
    Cai, Zhen-Wei
    Lippy, Jonathan
    Menichincheri, Maria
    Modugno, Michele
    Naglich, Joseph
    Penhallow, Becky
    Perez, Heidi L.
    Sack, John
    Schmidt, Robert J.
    Tebben, Andrew
    Yan, Chunhong
    Zhang, Liping
    Galvani, Arturo
    Lombardo, Louis J.
    Borzilleri, Robert M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (12) : 3951 - 3956
  • [38] Towards the next generation of dual Bcl-2/Bcl-xL inhibitors
    Varnes, Jeffrey G.
    Gero, Thomas
    Huang, Shan
    Diebold, R. Bruce
    Ogoe, Claude
    Grover, Paul T.
    Su, Mei
    Mukherjee, Prasenjit
    Saeh, Jamal Carlos
    MacIntyre, Terry
    Repik, Galina
    Dillman, Keith
    Byth, Kate
    Russell, Daniel John
    Ioannidis, Stephanos
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (14) : 3026 - 3033
  • [39] Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists
    Perez, Heidi L.
    Banfi, Patrizia
    Bertrand, Jay
    Cai, Zhen-Wei
    Grebinski, James W.
    Kim, Kyoung
    Lippy, Jonathan
    Modugno, Michele
    Naglich, Joseph
    Schmidt, Robert J.
    Tebben, Andrew
    Vianello, Paola
    Wei, Donna D.
    Zhang, Liping
    Galvani, Arturo
    Lombardo, Louis J.
    Borzilleri, Robert M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (12) : 3946 - 3950
  • [40] Subcellular distribution and function of Bcl-2 and Bcl-xL in the beta cell
    Luciani, D. S.
    Widenmaier, S.
    Yeung, J.
    McIntosh, C.
    Johnson, J. D.
    DIABETOLOGIA, 2008, 51 : S218 - S219